Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label international multicenter study of intravesical T3011 in BCG-unresponsive high-risk non-muscle invasive bladder cancer
CTR20253736Phase 2Active
- Sponsor
- InnoVen
- Start
- Jun 2025
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MVR-T3011 in non-muscle-invasive bladder cancer (NMIBC), sponsored by InnoVen. Started Jun 2025; status: active.
02
Drugs
MVR-T3011
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20253736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253736.